Passive hemagglutination assays (PHA) may be used t o detect IgA antibodies t o confirm clinical diagnoses of suspected IgA anaphylactic transfusion reactions. Passive hemagglutination inhibition assays (PHIA) may be used t o identify IgA-deficient blood donors whose plasma-containing components are transfused t o prevent anaphylactic transfusion reactions in prospective recipients at risk because of the presence of IgA antibodies. Using a standard PHA, we detected class-specific anti-lgA in 76.3% of 80 IgAdeficient patients with a history of an anaphylactic transfusion reaction, and in 21.7% of 97 asymptomatic IgA-deficient blood donors or their IgA-deficient family members. Using PHIA, we confirmed IgA deficiency (<0.05 mg/dL) for the donors of 525 plasma-containing blood components that were transfused without acute clinical reactions t o 48 IgA-
HE OCCURRENCE OF AN anaphylactic reaction dur-
ing a blood transfusion requires the exclusion of IgA deficiency andor the presence of anti-IgA before proceeding with additional transfusions of standard blood components. Suspected IgA anaphylactic transfusion reactions are confirmed when class-specific anti-IgA is detected in the serum of an IgA-deficient recipient.l-13 Clinically less severe, anaphylactoid transfusion reactions are attributed to subclass-(anti-IgA1 or -1gA2) or allotype-[anti-IgA2m(l) or -IgA2m(2)] specific IgA antibodies in persons with a normal concentration of total IgA.'.3.9.'4 Most laboratories test for IgA antibodies by passive hemagglutination assay (PHA) using group 0 red blood cells (RBCs) coated with serologically defined IgA multiple myeloma proteins as indicator cells."'s
In patients who have class-specific anti-IgA in their serum and a history of an anaphylactic transfusion reaction, subsequent transfusions of plasma-containing components (freshfrozen plasma, cryoprecipitated antihemophilic factor [AHF], platelets) require blood components collected from IgA-deficient donors. Typically, IgA-deficient donors are identified by screening random blood donors using immunodiffusion methods and by confirming true IgA deficiency (<0.05 mg/dL) by highly sensitive passive hemagglutination inhibition assays (PHIA).3.'"18 In the PHIA, the presence of IgA in the test sample results in inhibition of agglutination of IgA myeloma-coated group 0 red blood cells by standardized reagent anti-IgA.". '9 In this report, we describe the results of testing 328 IgAdeficient patients, healthy blood donors, or their family members for IgA antibodies by PHA. We also describe the outcome of transfusing 48 patients known to have anti-IgA and/ or to have a history of an anaphylactic reaction with plasmacontaining blood components that had been determined to be IgA-deficient by PHIA.
T

MATERIALS AND METHODS
Patients with anaphylactic reactions. Sera were obtained from 359 patients with a recent history of an anaphylactic or anaphylactoid transfusion reaction. These sera were collected in hospitals or blood centers from patients who had experienced acute clinically severe 
RESULTS
Patients with anaphylactic reactions.
Of 359 serum samples from patients with suspected IgA transfusion reactions, 59 (16.4%) had an abnormally low concentration of IgA (0.05 to 75 mg/dL) and 80 (22.3%) were IgA-deficient (<0.05 mg/dL) by PHIA ( Table I) . Class-specific anti-IgA was detected in 61 (76.3%) of the 80 sera from IgA-deficient t Anti-lgAPm(2).
* Anti-lgA2 and anti-lgA2m(l).
patients. Subclass-specific anti-IgA2 was detected in two patients with low concentrations of IgA. Subclass-specific anti-IgA2 and allotype-specific anti-IgA2m( l ) were detected in one IgA-deficient patient, and allotype-specific antiIgA2m(2) was detected in another ( Table I) . The median titer of class-specific anti-IgA in the serum of 63 IgA-deficient recipients with anaphylactic transfusion reactions was 640 (range, < 10 to > 10,240) (Fig 1) . The clinical severity of the reactions did not necessarily correlate with the serologic specificity(ies). Some patients with severe clinical reactions had only low-titer or undetectable anti-IgA.
IgA dejiciency in blood donors. IgA was not detectable by RID in 1 1 1 (0.34%) of 32,376 random blood donors. When these 11 1 sera were retested by PHIA, 87 (0.26%) were confirmed to be IgA-deficient. Of these 87 IgA-deficient sera, 27 (31.0%) contained class-specific anti-IgA. None of these 21 donors had a known history of blood transfusion. The frequency of IgA deficiency among the 32,376 blood donors was one in 372. One in 1,200 (0.08%) blood donors was IgA-deficient and also had class-specific anti-IgA detected by PHA.
Anti-IgA in asymptomatic IgA dejiciency.
In addition to the 87 sera from IgA-deficient blood donors, we tested 261 serum samples from other blood donors known to be IgAdeficient or from their IgA-deficient family members (Table  2) ; of the total 358 samples from IgA-deficient donors or their family members, class specific anti-IgA (alone or together with a subclass or allotype-specific antibody) was detected in 97 (27.1 %) ( Table 2 ). The median titer of classspecific anti-IgA in IgA-deficient blood donors was 120 (range, < l 0 to >1,024) (Fig 2) . Thus, there was considerable overlap in titers of anti-IgA among asymptomatic blood donors (Fig 2) compared with patients with anti-IgA and a history of an anaphylactic transfusion reaction (Fig I) .
Transfusion of IgA-deficient blood components. Five hundred twenty-five plasma-containing blood components from IgA-deficient blood donors were transfused without acute reactions to 48 patients with known anti-IgA andor a history of an anaphylactic transfusion reaction. These blood components were fresh-frozen plasma, or single-donor plasma (506 U), cryoprecipitated AHF (15 U), and platelets (pheresis; 4 U). Of 48 recipients, 38 underwent surgery, including six liver and two heart transplants. These statistics reflect most, but not all, IgA-deficient plasma-containing blood components supplied by American Red Cross Blood Services nationwide between 1985 and 1992 for patients with suspected IgA anaphylactic reactions. Not included are blood components supplied locally by IgA-deficient donors. but not reported to the Red Cross Rare Donor Registry. or IgA-deficient blood products supplied by non-Red Cross Blood Services.
Three patients with high-titer, class-specific anti-IgA had recurrent anaphylactic reactions when subsequently transfused with fresh-frozen plasma that was presumed to be IgAdeficient. On retesting these units of fresh-frozen plasma by PHIA, measurable, although low, concentrations of IgA were detected. A review of records showed that the donors' IgA concentrations had been determined to be IgA-deficient by a method less sensitive than PHIA. 
' l l DISCUSSION
Our findings confirm other reports that PHIA for IgA is sensitive and effective for identifying safe IgA-deficient plasma-containing blood components and preventing IgA anaphylactic transfusion reactions i n recipients with IgA antibodies and/or a history of an anaphylactoid transfusion reaction. This conclusion is based on the absence of acute clinical reactions when S25 plasma-containing blood components from donors determined to be IgA-deficient by PHIA were transfused in 48 patients at risk for IgA anaphylactic reactions.
Nevertheless, we cannot attribute unequivocally the absence of acute reactions in these 4X recipients to the fact that all subsequent transfusions were limited to IgA-deficient blood components. The relatively high frequency (one in 1,200) of class-spccilic anti-lgA detected by standard PHA in IgA-deficient donors, compared with the rarity of anaphy- Titer lactic reactions in transfusion patients. strongly suggests t h a t using the standard PHA for. anti-IzA lcatls to an overestilnation of persons who are presumed t o be at risk for clinically significant 1gA anaphylactic reactions. This overestimation potentially includes persons among these 4X recipients who may have had a n xqhylactic reaction unrelated t o transfusion and a coincidental IgA anlibody dctccted during the subsequent investigation. It is estimated that the incidence of IgA anaphylactic transfusion reactions is between I in 20.000 to 47.000 transfusions." I n the IO-year period 1982 t o 1992. 297. I 9 0 blood cotnponcnts wcte transfusrd a t Georgctown University Medical Center. Washington. DC.
During these I O years. approximately 0.9% of all component transfusions were investigated for adverse reactions. but no cases of IgA anaphylactic rcactions were idcntifictl (S. Novak, personal communication. JUILILW~ 1994). In Canada. the incidence of anaphylactic transfusion reactions has becn estimated to be I .3 per I.OOO.000 LJ blood or blood products transfused." As a consequence o f this nonspecificity o f PHA for IgA antibodies. a n excessive number of IgA-tleticient patients and healthy donors screened for lgA dcticicncy will be informed that they have anti-IgA i n their serum rrrrtl require IgA-deficient blood products for any future trnnsfusions. Such ;I lifetime requirement Inay have serious implications if, for exumple. urgently needed blood transfusions are clelayed while efforts are made to locate lgA-delicient blood With regard to IgA antibodies of limited speciticity. the issue of the nonspeciticity of PHA is morc complex. The only case report o f a fatal anaphylactic transfusion reaction associated with anti-IgA that we have bccn able to identify i n the medical literature involvcd a 57-yenr-old man who products. (Table 2) . Rivat et alZ3 screened 1.010 healthy blood donors by PHA using 12 diffcrent scrologically defined IgA myeloma proteins. They detectcd IgA antibodies of limited speciticity in S W . ;I fr-equcncy that did not differ significantly from that among patients with suspected IgA ;ulaphylactic reactions. Our finding of a disproportionally high frequency of anti-IgA i n health blood donors. compared with the rarity ofconfirlned IgA anaphylactic reactions in transfused paticnts, substantiates the impression of Mollison et al." who suggested that thc finding of IgA antibodics of limited specificity i n somc reports of anaphylactoid reactions "may have been.
at least to some extent. coincidental." They cite a series of six patient\ whose plasma contained IgA antibodies of limited specificity (titer seldom >72) and who had been transfused with standard blood component\ without reaction."."
Efforts to identify a morc specific marker for thc risk of an IgA anaphylactic transfusion rcaction have included attempts to detect IgE anti-lgA, hut with equivocal rewlts. Direct skin testing f o r reagin (ie. IgE anti-lgA) gave negativc results in one patient with a well-documented anaphylactic reaction associated with anti-IgA." Testing for IgE anti-lgA by the PrausnitL-Kustner passive transfer technique was negative i n another case.2 111 a previously reported study. sera from seven of I6 of our patients with anaphylactic or anaphylactoid reactions and anti-lgA by PHA had detectable IgE anti-lgA by radioimmunoassay (RIA).'" RIA detected IgE anti-IgA in two patients with symptomatic hypog~umm~~glob-ulinemia who had experienced well-documented recurrent anaphylactic reactions associated with anti-lgA by PHA after injcctions of immune serum globulin (gamma globulin)."' Such approaches t o a more specific laboratory diagnosis o f IgA anaphylactic reactions arc promising. Further research is needed to identify a marker more specific than hemugglutinating anti-IgA in patient\ a t risk for IgA anaphylactic tran\-fusion rcactions. While the current algorithm of PHA 
